• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Diseases
filarial icon

River blindness

Symptoms, transmission, and current treatments for filarial diseases

Home > Diseases
filarial icon

River blindness

Symptoms, transmission, and current treatments for filarial diseases

  • Overview
  • Facts
  • Projects & achievements
  • Target product profile

What are filarial diseases?

Filarial diseases are caused by parasitic worms that are transmitted by the bite of blood-feeding insects. This debilitating group of diseases includes river blindness and lymphatic filariasis (commonly known as elephantiasis).

What is river blindness?

Onchocerciasis, commonly known as river blindness, is a filarial disease caused by the parasitic nematode worm Onchocerca volvulus. People are infected by worms transmitted by the bite of blood-sucking blackflies, which breed in fast-flowing rivers. 

River blindness is not usually fatal, but it can cause devastating disability. In the human body, the adult worms produce embryonic larvae (microfilariae) that migrate to the skin, eyes and other organs. The worms can cause severe itching, disfiguring skin conditions, impaired vision, and irreversible blindness.

Efforts to eliminate river blindness are hampered in some areas by another parasitic infection: Loiasis (also known as Loa loa or ‘African eye worm’). People living with a high amount of Loa loa larvae (microfilariae) in their blood are at risk of life-threatening complications if they receive ivermectin, the most common treatment for river blindness.

What is the impact of river blindness?

  • 250 million people at risk
  • 19 million people infected with river blindness
  • 1.15 million people with vision loss
  • 99% of people infected live in 31 African countries, predominantly in West and Central Africa
  • 14.6 million people suffer from filarial skin diseases

What are current treatments for river blindness?

Current treatment for river blindness is based on repeated mass drug administration (MDA) of ivermectin to everyone living in an affected area. These efforts are directed by the country’s national control programmes and supported by international organisations, such as the World Health Organization (WHO), ESPEN, and the Task Force for Global Health. The drugs kill juvenile worms and temporarily sterilize adult worms. The adult worms remain alive in the body, eventually producing new offspring, often before the next MDA takes place. As a result, MDA must be repeated for many years.

Ivermectin is safe and has been used widely, however it:

  • Requires many years of repeatedly taking the drug to reduce disease burden and eventually achieve elimination
  • Cannot be used in areas where people also are burdened with high levels of Loa loa (African eye worm) because it can result in severe and potentially fatal side effects
  • Cannot be given to women who are pregnant, and there is currently no suitable formulation for small children
  • Only partly improves or prevents river blindness symptoms such as itching, dermatitis, and blindness because people continue to be affected by the adult worms living in their bodies

What new treatments for river blindness are needed?

WHO has set targets for the elimination of river blindness in 12 countries by 2030 in its NTD Roadmap. Even though countries are making steady progress, and elimination programmes continue, the WHO also notes that the lack of effective treatments is making reaching the targets more difficult.

New drugs that can kill adult worms and are safe for people who also have Loa loa are urgently needed.

What river blindness treatments are we working on?

We aim to deliver a safe, effective, affordable, and field-adapted drug that can kill adult filarial worms (a ‘macrofilaricide’) and be used for prevention or individual treatment.

Find out about our work developing treatments for river blindness.

How do you get river blindness?

  • Insect bites: river blindness is transmitted through the bite of a blackfly infected with Onchocerca volvulus worms

What are the symptoms of river blindness?

River blindness is not usually fatal, but if left untreated, it causes long-term suffering, chronic illness, and permanent disability, including:

  • visual impairment and blindness
  • severe itching
  • dermatitis
  • nodules under the skin (around adult worms)

How is river blindness diagnosed?

  • River blindness is diagnosed by identifying juvenile worms in skin snips.
  • In patients with nodules in the skin, the nodule can be surgically removed and examined for adult worms.
  • Infections in the eye can be diagnosed with a slit-lamp examination of the front part of the eye where the larvae or the lesions they cause are visible.

Antibody tests are available but have limited use in areas where river blindness is commonly found because they cannot differentiate between past and current infection. Several rapid diagnostic tests (RDTs) are under development, but currently lack the sensitivity and specificity needed for use in national elimination programmes.

Accurate diagnosis of Loa loa coinfection is important when considering treatment with ivermectin, since rapid killing of large numbers of juvenile Loa loa worms can cause serious and potentially fatal side effects.

More information

  • WHO factsheet

Last updated: November 2025

‘When the darkness came over me, not even my glasses were any use to see. I felt desperate, abandoned by society.’

Professor Alfonse, a former teacher, fled conflict in the city to live in the greener pastures of Makana. While tending to his fields, he was bitten by blackflies that transmit river blindness. He dreams for more research and innovation for this neglected disease.

watch his story

Making medical history for neglected patients

We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them

Chagas disease

Causes heart and vital organ damage, after people are bitten by blood-sucking bugs

We delivered the first-ever treatment for children; now we’re searching for new drug candidates and working to boost access to care

Patient medical examination

Cryptococcal meningitis

Without treatment, deadly for thousands of people with advanced HIV

We’re working to improve access to life-saving treatments and developing an easier-to-use formulation

Cutaneous leishmaniasis

Leaves disfiguring, life-long scars that lead to severe social stigma

We’re working to develop safer, shorter treatments for this disabling disease

Dengue

Rapidly spreading climate-sensitive disease with no specific treatment

We’re building a global partnership with dengue-endemic countries to develop a first treatment

Hepatitis C

Millions are left without treatment even though effective drugs exist

We’ve delivered a treatment as simple, safe, and effective as the best drugs available today – at a fraction of the cost 

Mycetoma

Often ends in amputation​, after people get infected from stepping on a thorn

We conducted the world’s first trial for an alternative to current treatments, which are toxic and difficult to administer

Paediatric HIV

Without treatment, half of children die before their second birthday

We’ve developed a strawberry-flavoured treatment to meet the needs of children long neglected by the global HIV response

Healthcare workers in a hospital

Pandemic Preparedness

The COVID-19 pandemic intensified global health inequalities

We’re bringing together partners and accelerating research to prepare for future viral pandemics in low-resource settings

Parasitic worms

Cause debilitating illness, social exclusion, and long-term disability

We’re working across multiple diseases to develop missing cures that can prevent lasting harm

Sleeping sickness

Transmitted by the bite of a tsetse fly and causes severe neurological disorders

We delivered a revolutionary new drug to replace toxic treatments, and have ongoing trials to eliminate this disease

Chagas disease

Cryptococcal meningitis

Cutaneous leishmaniasis

Dengue

Hepatitis C

Mycetoma

Paediatric HIV

Pandemic Preparedness

Parasitic worms

Sleeping sickness

VIEW ALL DISEASES

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license